Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
TREAT TB
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
OTHER AREAS OF OUR WORK IN TUBERCULOSIS
You might also be interested in our work on child and adolescent TB and TB-HIV, TB-diabetes and co-morbidities.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
Learn more
Understand the issues with our fact sheets
DR-TB Union news
Combating the tridemic: new guidelines, masking and altruism
An Editorial in a forthcoming issue of the IJTLD highlights the impact of the tridemic of COVID-19, influenza and respiratory syncytial virus. The preprint is free to read.
F.D.A. Ruling on Vuse E-Cigarettes Will Likely Hinder Public Health, Hurt Kids
British American Tobacco (BAT) and its American unit, R.J. Reynolds, are undoubtedly having a very good week, but the same cannot be…
COVID-19 and TB control in immigrant communities
Letter to the editors highlighting the disparity of impact of COVID-19 and TB on immigrant communities and the need to have affordable healthcare.
“The tobacco industry is exploiting the COVID-19 pandemic to protect profits and undermine tobacco control policy.”
Emma Green is The Union’s Project Manager for STOP (Stopping Tobacco Organizations and Products), the global tobacco industry…
Transforming essential services for tuberculosis during the COVID-19 pandemic: lessons from New York City
To ensure that scientific research of immediate concern is shared as rapidly as possible, The Union is fast-tracking accepted articles…
DR-TB publications
Compliance with intermittent preventive malaria treatment in pregnancy at a tertiary hospital in Sierra Leone
In this article, part of the TB, HIV and Malaria Series to be published in the Q2 issue of PHA, the authors examine uptake of intermittent preventive treatment in pregnancy in Sierra Leone, showing low compliance with the recommended minimum of three doses, largely associated with insufficient antenatal care contacts.
Mapping Malaria Hotspots through Spatial and Spatio-Temporal Analysis in Sierra Leone, 2021-2024
In this article part of the TB, HIV and Malaria Series to be published in the Q2 issue of PHA, the authors analyse the spatial and temporal distribution of malaria in Sierra Leone, identifying persistent hotspots and no significant association with rainfall. The findings highlight the need for targeted, subnational interventions to address persistent hotspots.
Parenteral artesunate compliance and hospital outcomes in children under-five with suspected severe malaria in Sierra Leone
In this article, part of the TB, HIV and Malaria Series to be published in the Q2 issue of PHA, the authors assess adherence to national severe malaria management guidelines in children under five in Sierra Leone and its association with hospital outcomes, highlighting suboptimal artesunate dosing and related adverse outcomes.